Pulmonary Fibrosis Pipeline Progresses as 110+ Pharma Companies Advance 140+ Novel Lung Disease Therapies, Finds DelveInsight | Bristol-Myers Squibb, PureTech Health, United Therapeutics, Boehringer Ingelheim, Insilico Medicine, Tvardi Therapeutics

DelveInsight's "Pulmonary Fibrosis - Pipeline Insight, 2026" report provides comprehensive insights about 110+ companies developing over 140 pipeline drugs in the Pulmonary Fibrosis pipeline landscape. It covers the Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Pulmonary Fibrosis treatment landscape. Learn more about the evolving Pulmonary Fibrosis pipeline today @ https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Pulmonary Fibrosis Pipeline Report

• In October 2025, the U.S. FDA approved Boehringer Ingelheim's Jascayd (nerandomilast) tablets for the treatment of idiopathic pulmonary fibrosis (IPF), marking the first new therapy authorized for IPF in over a decade.
• In January 2026, Agomab Therapeutics announced positive interim results from its Phase I study of AGMB-447, an inhaled small molecule inhibitor intended for the treatment of IPF.
• In January 2026, the US FDA lifted the Partial Clinical Hold on Redx Pharma's zelasudil (RXC007) Phase IIa trial in Idiopathic Pulmonary Fibrosis.
• In September 2025, United Therapeutics reported positive Phase III TETON-2 trial results for inhaled treprostinil (Tyvaso), showing a significant improvement in forced vital capacity (FVC) in patients with IPF.
• In June 2025, Insilico Medicine announced positive results from its Phase 2a study of rentosertib, an AI-designed drug that demonstrated improved lung function in people living with IPF.
• In December 2025, PureTech Health completed a successful End-of-Phase 2 meeting with the FDA regarding the development of deupirfenidone (LYT-100) for IPF treatment.
• The Pulmonary Fibrosis pipeline features 110+ active players advancing 140+ pipeline therapies across multiple stages, from discovery through Phase III clinical evaluation.
• Bristol-Myers Squibb holds a prominent position in the pipeline with BMS-986278, an oral LPA1 antagonist currently in Phase III development.
• Leading companies in the Pulmonary Fibrosis space include Bristol-Myers Squibb, PureTech Health, United Therapeutics, Boehringer Ingelheim, Insilico Medicine, Tvardi Therapeutics, Melius Pharma, and others.

Download for updates and the latest revolution in Pulmonary Fibrosis care @ https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Pulmonary Fibrosis Emerging Drugs Profile

• BMS-986278: Bristol-Myers Squibb
BMS-986278 is a potential first-in-class, oral lysophosphatidic acid receptor 1 (LPA1) antagonist designed to reduce the fibrotic process in the lungs. LPA1 signaling is critically involved in the development of pulmonary fibrosis, making it a promising therapeutic target. The FDA has granted BMS-986278 both Fast Track and Orphan Drug designations for the treatment of IPF. Currently, the candidate is being evaluated in Phase III clinical development to assess its ability to slow lung function decline.

• Jascayd (Nerandomilast): Boehringer Ingelheim
Jascayd (nerandomilast) is a phosphodiesterase 4 (PDE4) inhibitor that recently concluded a successful Phase III clinical trial (FIBRONEER-ILD), demonstrating a significant slowing of lung function decline compared to placebo. It was approved by the U.S. FDA in October 2025 as the first new treatment option for adults with Idiopathic Pulmonary Fibrosis in over a decade. Its favorable safety profile and ease of use, combined with its ability to reduce functional decline, position it as a new standard of care in the evolving treatment landscape.

• Deupirfenidone (LYT-100): PureTech Health
Deupirfenidone is a deuterated form of pirfenidone designed to improve upon the established standard of care by slowing lung degeneration with potentially better tolerability. In September 2025, PureTech shared new data from its Phase 2b ELEVATE IPF trial, showing stabilized lung function in participants who transitioned to deupirfenidone. Results from the trial revealed that deupirfenidone successfully met its primary and secondary endpoints, reinforcing its potential as a future pillar of IPF management.

For more information on the Pulmonary Fibrosis Emerging Drugs Profile, download DelveInsight's comprehensive Pulmonary Fibrosis Pipeline Insight report @ https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Pulmonary Fibrosis Pipeline Report Provides

• Detailed insights about companies developing therapies for Pulmonary Fibrosis, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis treatment.
• Pulmonary Fibrosis companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pulmonary Fibrosis drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Pulmonary Fibrosis market.

Learn more about Pulmonary Fibrosis drug opportunities in our comprehensive Pulmonary Fibrosis pipeline report @ https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Pulmonary Fibrosis Companies and Competitive Landscape

There are 110+ key companies, including Bristol-Myers Squibb, PureTech Health, United Therapeutics, Boehringer Ingelheim, Insilico Medicine, Tvardi Therapeutics, Melius Pharma, Resproly, and others, developing therapies for Pulmonary Fibrosis, with several candidates now in advanced Phase III stages.

DelveInsight's Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Pulmonary Fibrosis products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Pulmonary Fibrosis treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Pulmonary Fibrosis Pipeline Report

• Coverage: Global
• Pulmonary Fibrosis Companies: Bristol-Myers Squibb, PureTech Health, United Therapeutics, Boehringer Ingelheim, Insilico Medicine, Tvardi Therapeutics, and others.
• Pulmonary Fibrosis Therapies: BMS-986278, Jascayd (nerandomilast), deupirfenidone (LYT-100), Tyvaso, rentosertib, and other undisclosed pipeline candidates.
• Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.